Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05365438 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Atmeg (Atorvastatin and Omega-3 Combination) and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Dec 31, 2025 to Dec 31, 2026v5
  2. Primary endpoint revised
    • Eligibility criteria revised
    • Secondary endpoints: 9 to 7
    v4
  3. Primary completion date: Mar 31, 2024 to Dec 31, 2025
    • Study completion date: Dec 31, 2024 to Dec 31, 2026
    v3
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jun 1, 2022 to Oct 1, 2022
    • Study sites: 0 to 1
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a randomized controlled study to assess the effect of atorvastatin and omega 3 combination therapy compared with atorvastatin and ezetimibe combination therapy in Korean T2DM patients with asymptomatic atherosclerosis.
Trial Details
NCT Number NCT05365438
Lead Sponsor Seoul National University Bundang Hospital
Collaborators: Korea United Pharm. Inc.
Conditions
(from sponsor)		 Dyslipidemias, Atherosclerosis, Diabetes Mellitus, Type 2
Related terms Atherosclerosis, Diabetes Mellitus, Type 2, Dyslipidemias
Enrollment 105 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov